Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes

Clofutriben is a novel, once-daily, oral HSD-1 inhibitor that reduces excess intracellular cortisol, a new precision approach to a common underlying driver of metabolic dysfunction

The release as fetched from its publisher. sparrowpharma.com ↗